Zevalin ibritumomab tiuxetan regulatory update

FDA accepted for review a post-approval supplement from Spectrum for Zevalin ibritumomab tiuxetan to remove the requirement for Zevalin indium-111 pre-treatment imaging evaluation. The PDUFA date is N...